Mexidol® and Mexidol® FORTE 250 are reference (original) preparations

LLC “Scientific Production Company “PHARMASOFT” reports receipt of a letter (No. 20-3/545 of 13.04.2020) from the Department for State Regulation of the Circulation of Medicines of the Ministry of Health of the Russian Federation which confirms that the following drugs are reference (original) ones.

Read More

When a great victory is needed

LLC "SPC "PHARMASOFT" announces registration of a new dosage of the drug Mexidol® - Mexidol® FORTE 250, film-coated tablets, 250 mg, RU No. LP-004831 of April 26, 2018.

"Mexidol® FORTE 250" is a double dosage of the active ingredient in one film-coated tablet for patients who require an increased dosage, including patients with combined pathology. "Mexidol® FORTE 250" is a reference (original) preparation of ethylmethylhydroxypyridine succinate, the only preparation with active substance ethylmethylhydroxypyridine succinate with a double dosage. "Mexidol® FORTE 250" - a high safety profile.

Read More

Results of the most important study on effectiveness and safety of Mexidol (EPICA) have been published

LLC "SPC "PHARMASOFT" informed about completion of randomized, double-blind, multicenter, placebo-controlled in parallel groups study of effectiveness and safety of Mexidol in long-term sequential therapy in patients with hemispheric ischemic stroke EPICA in acute and early rehabilitation periods. The results of the study have been published (Stakhovskaya L.V., Shamalov N.A., Khasanova D.R., Melnikova E.V., et al. Journal of Neurology & Psychiatry named after S.S. Korsakov2017; 3 (2):55-65; Supplement "Stroke").

Read More